TPP raises £9.6 million for early drug development in Scotland
This article was originally published in Scrip
In a move that will boost Scotland's growing reputation as a base for life sciences research, the UK-based drug development company, TPP Global Development, has decided to set up its new headquarters in the Edinburgh BioQuarter. It has also raised £9.6 million for use in developing early-stage preclinical drug candidates.
You may also be interested in...
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.